STAT+: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept

Patrick Soon-Shiong's claims about transforming pancreatic cancer treatment with novel immunotherapies are criticized for lacking clinical evidence, with a gap between his promises and actual FDA-approved outcomes. The article highlights his history in treating pancreatic cancer and the 'Bioshield' mission, while noting financial self-interest and regulatory scrutiny.